Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Travoprost

FDA-approved product (solution/drops, ophthalmic), marketed as Idose Tr, Izba, Travatan and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Travoprost
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Glaucoma
  • Ocular hypertension
  • Open-angle glaucoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Prostaglandin analogues
FDA pharmacologic class
Prostaglandin Analog FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Travoprost in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Travoprost with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

    NCT07495852 · start 2026-02-17

    Registered record
    Registry ID
    NCT07495852
    Conditions
    Glaucoma
    Interventions
    Gen 2 Travoprost Intracameral Implant; Timolol eye drops 0.5%; Sham Procedure; placebo eye drops
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-02-17
    Completion
    2032-03
    Enrolment
    510

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionGen 2 Travoprost Intracameral Implant; Timolol eye drops 0.5%; Sham Procedure; placebo eye drops
    PhasePhase 3
    Registry statusRecruiting

  • Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg

    NCT07400926 · start 2025-12-17

    Registered record
    Registry ID
    NCT07400926
    Conditions
    Open Angle Glaucoma (OAG); Ocular Hypertension (OH)
    Interventions
    Travoprost
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-12-17
    Completion
    2026-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma (OAG); Ocular Hypertension (OH)
    InterventionTravoprost
    PhaseNot recorded
    Registry statusRecruiting

  • Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

    NCT07075718 · start 2025-06-12

    Registered record
    Registry ID
    NCT07075718
    Conditions
    Glaucoma
    Interventions
    Gen 2 Travoprost Intracameral Implant; Timolol eye drops 0.5%; Sham Procedure; Placebo eye drops
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-06-12
    Completion
    2032-03
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionGen 2 Travoprost Intracameral Implant; Timolol eye drops 0.5%; Sham Procedure; Placebo eye drops
    PhasePhase 2
    Registry statusRecruiting

  • Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone

    NCT06848946 · start 2025-01-13

    Registered record
    Registry ID
    NCT06848946
    Conditions
    Glaucoma, Open-angle; Ocular Hypertension (OHT); Phacoemulsification Cataract Surgery
    Interventions
    iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery; Sham procedure in conjunction with cataract surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-01-13
    Completion
    2027-06
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-angle; Ocular Hypertension (OHT); Phacoemulsification Cataract Surgery
    InterventioniDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery; Sham procedure in conjunction with cataract surgery
    PhasePhase 4
    Registry statusRecruiting

  • PSLT Compared to Prostaglandin Analogue Eye Drops

    NCT05241938 · start 2021-09-01

    Registered record
    Registry ID
    NCT05241938
    Conditions
    Open Angle Glaucoma; Ocular Hypertension
    Interventions
    PSLT; Prostaglandin analogue eye drops
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-09-01
    Completion
    2022-12-20
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma; Ocular Hypertension
    InterventionPSLT; Prostaglandin analogue eye drops
    PhaseNot applicable
    Registry statusUnknown

  • Performance of the Travoprost Intraocular Implant

    NCT06582732 · start 2021-03-10

    Registered record
    Registry ID
    NCT06582732
    Conditions
    Glaucoma, Open-Angle; Ocular Hypertension
    Interventions
    Travoprost Intracameral Implant exchanged at Month 12; Travoprost Intracameral Implant exchanged at Month 3; Travoprost Intracameral Implant exchanged at Month 6; Travoprost Intracameral Implant exchanged at Month 24; Travoprost intracameral implant exchanged at Month 21; Travoprost intracameral implant exchanged at Month 18; Travoprost intracameral implant exchanged at Month 15
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-03-10
    Completion
    2023-11-02
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-Angle; Ocular Hypertension
    InterventionTravoprost Intracameral Implant exchanged at Month 12; Travoprost Intracameral Implant exchanged at Month 3; Travoprost Intracameral Implant exchanged at Month 6; Travoprost Intracameral Implant exchanged at Month 24 +3 more
    PhasePhase 2
    Registry statusCompleted

  • Interval Intraocular Pressure in Intravitreal Injection Study

    NCT04868175 · start 2019-10-01

    Registered record
    Registry ID
    NCT04868175
    Conditions
    Glaucoma; Intraocular Pressure
    Interventions
    Timolol; Travatan; Hypromellose
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-10-01
    Completion
    2021-04-01
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Intraocular Pressure
    InterventionTimolol; Travatan; Hypromellose
    PhaseNot applicable
    Registry statusCompleted

  • Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients

    NCT04461249 · start 2019-06-01

    Registered record
    Registry ID
    NCT04461249
    Conditions
    Primary Open Angle Glaucoma
    Interventions
    Latanoprost 0.005% Ophthalmic Solution; Travoprost 0.004% ophthalmic solution; Tafluprost Ophthalmic 0.0015% Ophthalmic Solution
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-06-01
    Completion
    2020-04-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open Angle Glaucoma
    InterventionLatanoprost 0.005% Ophthalmic Solution; Travoprost 0.004% ophthalmic solution; Tafluprost Ophthalmic 0.0015% Ophthalmic Solution
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert

    NCT04061044 · start 2018-07-10

    Registered record
    Registry ID
    NCT04061044
    Conditions
    Open Angle Glaucoma and Ocular Hypertension
    Interventions
    Ophthalmic Insert
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-07-10
    Completion
    2020-09-22
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma and Ocular Hypertension
    InterventionOphthalmic Insert
    PhasePhase 3
    Registry statusCompleted

  • Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT

    NCT02914509 · start 2016-11-07

    Registered record
    Registry ID
    NCT02914509
    Conditions
    Open Angle Glaucoma; Ocular Hypertension
    Interventions
    Travoprost; Placebo Vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-11-07
    Completion
    2019-03-30
    Enrolment
    565

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma; Ocular Hypertension
    InterventionTravoprost; Placebo Vehicle
    PhasePhase 3
    Registry statusCompleted

  • Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

    NCT02796560 · start 2016-07-01

    Registered record
    Registry ID
    NCT02796560
    Conditions
    Glaucoma, Primary Open Angle; Ocular Hypertension
    Interventions
    Brand name travoprost; Generic travoprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-07-01
    Completion
    2017-09-12
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Primary Open Angle; Ocular Hypertension
    InterventionBrand name travoprost; Generic travoprost
    PhasePhase 4
    Registry statusCompleted

  • Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure

    NCT02003391 · start 2013-12

    Registered record
    Registry ID
    NCT02003391
    Conditions
    Open Angle Glaucoma; Ocular Hypertension
    Interventions
    Beta-blocker monotherapy; Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-12
    Completion
    2015-05
    Enrolment
    157

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma; Ocular Hypertension
    InterventionBeta-blocker monotherapy; Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution
    PhasePhase 4
    Registry statusCompleted

  • Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma

    NCT01845038 · start 2013-04

    Registered record
    Registry ID
    NCT01845038
    Conditions
    Glaucoma
    Interventions
    OTX-TPa ~4µg/day over 2 mos. with natural tears drops; OTX-TPb ~3µg/day over 3 months with natural tears drops; Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-04
    Completion
    2014-05
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionOTX-TPa ~4µg/day over 2 mos. with natural tears drops; OTX-TPb ~3µg/day over 3 months with natural tears drops; Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug
    PhasePhase 1
    Registry statusCompleted

  • Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents

    NCT02873806 · start 2013-03

    Registered record
    Registry ID
    NCT02873806
    Conditions
    Open-angle Glaucoma
    Interventions
    Implantation of two iStent inject micro-bypass stents; Topical travoprost; Two iStent inject micro-bypass stents; Tobramycin; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-03
    Completion
    2019-11-08
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-angle Glaucoma
    InterventionImplantation of two iStent inject micro-bypass stents; Topical travoprost; Two iStent inject micro-bypass stents; Tobramycin +1 more
    PhasePhase 4
    Registry statusCompleted

  • An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®

    NCT01664039 · start 2012-09

    Registered record
    Registry ID
    NCT01664039
    Conditions
    Glaucoma; Ocular Hypertension
    Interventions
    Travoprost 0.004% ophthalmic solution; Bimatoprost 0.01% ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-09
    Completion
    2014-06
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Ocular Hypertension
    InterventionTravoprost 0.004% ophthalmic solution; Bimatoprost 0.01% ophthalmic solution
    PhasePhase 4
    Registry statusCompleted